Bacteriophage infection and killing of intracellular Mycobacterium abscessus

mBio. 2024 Jan 16;15(1):e0292423. doi: 10.1128/mbio.02924-23. Epub 2023 Dec 7.

Abstract

As we rapidly approach a post-antibiotic era, bacteriophage (phage) therapy may offer a solution for treating drug-resistant bacteria. Mycobacterium abscessus is an emerging, multidrug-resistant pathogen that causes disease in people with cystic fibrosis, chronic obstructive pulmonary disease, and other underlying lung diseases. M. abscessus can survive inside host cells, a niche that can limit access to antibiotics. As current treatment options for M. abscessus infections often fail, there is an urgent need for alternative therapies. Phage therapy is being used to treat M. abscessus infections as an option of last resort. However, little is known about the ability of phages to kill bacteria in the host environment and specifically in an intracellular environment. Here, we demonstrate the ability of phages to enter mammalian cells and to infect and kill intracellular M. abscessus. These findings support the use of phages to treat intracellular bacterial pathogens.

Keywords: Mycobacterium abscessus; bacteriophage therapy; intracellular bacteria; macrophages; nontuberculous mycobacteria.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacteriophages*
  • Cystic Fibrosis* / microbiology
  • Humans
  • Mammals
  • Mycobacterium abscessus*

Substances

  • Anti-Bacterial Agents